Centene Raises Full-Year 2022 Financial Guidance, Cites Redetermination Delay as Major Reason

During its investor update on June 17, Centene Corp. announced it had increased its adjusted diluted full-year earnings per share (EPS) guidance to between $5.55 and $5.70, up from its April range of between $5.40 and $5.55. The health insurance company also raised its projected annual premium and service revenues by $2 billion to between $134.3 billion and $136.3 billion.

Centene’s executives attributed much of the increase to its better-than-expected performance, particularly in the health insurance exchange market, as well as the delay in the restart of Medicaid eligibility redeterminations.

0 Comments
© 2022 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

wall-street-sign
May 12

Centene Plans to Sell Magellan Rx, PANTHERx Rare for $2.8 Billion

READ MORE
businessmen-making-calculation
March 25

New Centene CEO London Will Bring Tech, Innovation Chops to Her Role

READ MORE
st-louis-skyline
March 4

Departing Neidorff Leaves Legacy of Major Growth at Centene

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today